Payment overview · 2025
General Payments
$74.97
3 reported records · 2 companies
Healthcare provider profile · identity verified
John Batin, P.A.-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · YUCCA VALLEY, CA · NPI 1902017700
Verified facts
What the public records show
CMS Open Payments records show John Batin, P.A.-C received $74.97 in general payments during 2025 across 3 reported records.
Lilly USA, LLC accounted for 65.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.29 | 65.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.68 | 34.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $74.97 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.29 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.29 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 850 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 68 |
| Gabapentin | Gabapentin | 260 | 67 |
| Lisinopril | Lisinopril | 257 | 72 |
| Omeprazole | Omeprazole | 236 | 72 |
| Trazodone Hcl | Trazodone Hcl | 233 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 58 |
| Losartan Potassium | Losartan Potassium | 192 | 55 |
| Metformin Hcl | Metformin Hcl | 188 | 48 |
| Furosemide | Furosemide | 181 | 44 |
| Potassium Chloride | Potassium Chloride | 169 | 44 |
| Simvastatin | Simvastatin | 164 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 46 |
| Benazepril Hcl | Benazepril Hcl | 146 | 37 |
| Terazosin Hcl | Terazosin Hcl | 140 | 30 |
| Oxybutynin Chloride | Oxybutynin Chloride | 129 | 33 |
| Famotidine | Famotidine | 123 | 31 |
| Baclofen | Baclofen | 119 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 32 |
| Ozempic | Semaglutide | 116 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 22 |
| Tramadol Hcl | Tramadol Hcl | 107 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 33 |
| Eliquis | Apixaban | 103 | 25 |
| Lorazepam | Lorazepam | 100 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 41 |
| Breo Ellipta | Fluticasone/Vilanterol | 91 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 87 | 22 |
| Sertraline Hcl | Sertraline Hcl | 87 | 24 |
| Carvedilol | Carvedilol | 83 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 72 | 14 |
| Montelukast Sodium | Montelukast Sodium | 72 | 18 |
| Alendronate Sodium | Alendronate Sodium | 69 | 19 |
| Atenolol | Atenolol | 66 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 16 |
| Glimepiride | Glimepiride | 65 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 22 |
| Alprazolam | Alprazolam | 61 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 18 |
| Ibuprofen | Ibuprofen | 59 | 26 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 14 |
| Fenofibrate | Fenofibrate | 58 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 22 |
| Azithromycin | Azithromycin | 51 | 39 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Spironolactone | Spironolactone | 50 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | 12 |
| Cephalexin | Cephalexin | 47 | 33 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Prednisone | Prednisone | 47 | 27 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Pregabalin | Pregabalin | 46 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 45 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Nystatin | Nystatin | 37 | 17 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 17 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 11 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Cartia Xt | Diltiazem Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $74.97 · 3 records | Lilly USA, LLC | Dexcom G6 Transmitter, MOUNJARO, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error